DELIVERING BREAKTHROUGHS
Path to Progress
Novel AAV capsids born from Voyager’s RNA-driven TRACERTM screening platform hold promise to target desired cells and tissues with greater specificity, at lower doses, and with fewer off-target risks than conventional AAV serotypes. TRACER capsids power internal product development and external partnerships with the goal of elevating the field of gene therapy to its highest potential.1
Equipped for the Journey
We see each step in our journey as progress toward unlocking the full potential of gene therapy. This is an opportunity to evolve, innovate, and close in on this breakthrough that has enormous promise to change the trajectory of disease and positively alter the lives of millions of people.
1 Nonnenmacher, et al. “RNA-driven Evolution of AAV Capsid Libraries Identifies Variants with High Transduction Efficiency in Non-Human Primate Central Nervous System.” ASGCT 2021.
In the News
Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting
Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid improved transduction in multiple CNS regions and cell types in non-human primates with partial
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results
Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™ AAV9- and AAV5-derived capsids Preclinical data to be presented at the ASGCT Annual Meeting to demonstrate reduction of
